SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
Status:
Completed
Trial end date:
2019-11-07
Target enrollment:
Participant gender:
Summary
This is a phase 2a, proof-of-concept, 26-week, double-blind, multicenter, randomized,
parallel group, placebo-controlled study to compare the efficacy and safety of treatment with
SUVN-502 to placebo treatment in subjects with moderate Alzheimer's disease receiving stable
doses of donepezil HCl and memantine HCl.